Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05648734
Other study ID # MD.21.09.526 - 2021/09/12
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 10, 2022
Est. completion date September 15, 2022

Study information

Verified date December 2022
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.


Description:

This study is a prospective and retrospective cohort study in which post COVID-19 patients who are following up at post COVID-19 clinic are evaluated regarding presence and degree of Post COVID-19 Pulmonary Fibrosis (PCPF) in relation to anti-inflammatory and/or anti-fibrotic drugs. Adult patients who have COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and according to WHO severity classification are (Moderate, severe, or critical) and has received either: - Corticosteroids alone (≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge) - Group A. - Corticosteroids in combination with Colchicine (1 mg/day for ≥ 10 days) - Group B. - Corticosteroids in combination with Pirfenidone (267 mg TID for ≥ 14 days) - Group C. - Corticosteroids in combination with Colchicine and Pirfenidone (for ≥ 14 days) - Group D. Pulmonary function test: Spirometry: measurement of lung volumes and capacities (forced expiratory volume in first second FEV1, Forced Vital Capacity FVC, FEV1/FVC and FEF25/75) after 1 month and 3 months of the onset of symptoms. Radiological scoring: Baseline High resolution CT scan of the chest will be performed at baseline, 1 month and 3 months after onset of symptoms. Chest CT-Severity Scoring (Chest CT-SS) for assessing COVID-19 burden on the initial scan will be calculated. This score uses lung opacification as a surrogate for extension of the disease in the lungs. According to the anatomic structure, the 18 segments of both lungs were divided into 20 regions, in which the posterior apical segment of the left upper lobe was subdivided into apical and posterior segmental regions, whereas the anteromedial basal segment of the left lower lobe was subdivided into anterior and basal segmental regions. The lung opacities in all the 20 lung regions were subjectively evaluated on chest CT images using a system attributing score of 0, 1, and 2 if parenchymal opacification involved 0%, less than 50%, or equal to or more than 50% of each region, respectively. The CT-SS was defined as the sum of the individual scores in the 20 lung segment regions, which may range from 0 to 40 points


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date September 15, 2022
Est. primary completion date June 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients who have COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and according to WHO severity classification are (Moderate, severe, or critical) and has received either: Corticosteroids alone. - Corticosteroids in combination with Colchicine. - Corticosteroids in combination with Pirfenidone. - Corticosteroids in combination with Colchicine and Pirfenidone. Exclusion Criteria: - None COVID-19 pneumonia. - Patients with previous parenchymal lung disease. - Patients receiving anti-fibrotic or anti-inflammatory drugs due to other chronic disease. - Patients who received anti-fibrotic and or ant inflammatory drugs for duration and or doses less than presumed or those who reported noncompliance to treatment. - Patients with uncontrolled comorbidities. - Patients who develop severe intolerable side effects or derangement of liver enzymes more than 5 folds. - Pregnant ladies with COVID-19 pneumonia.

Study Design


Intervention

Drug:
Corticosteroids alone
(= 20 mg prednisolone or its equivalent for = 10 days after hospital discharge)
Corticosteroids + Colchicine
(= 20 mg prednisolone or its equivalent for = 10 days) + Colchicine (1 mg/day for = 10 days)
Corticosteroids + Pirfenidone
(= 20 mg prednisolone or its equivalent for = 10 days) + Pirfenidone (267 mg TID for = 14 days)
Corticosteroids + Colchicine + Pirfenidone for = 14 days
(= 20 mg prednisolone or its equivalent for = 10 days) + Colchicine (1 mg/day for = 10 days) + Pirfenidone (267 mg TID for = 14 days)

Locations

Country Name City State
Egypt Mansoura University Mansoura Dakahlia

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pulmonary Functions Test Change in FVC from 1 month to 3 months follow up after hospital discharge 8 weeks
Primary Radiological scoring Change in Chest CT Severity Scoring (Chest CT-SS) from 1 month to 3 months follow up after hospital discharge compared to baseline CT Chest scan 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06073002 - Effects of a Home-Based Exercise Intervention in Subjects With Long COVID N/A
Completed NCT05047952 - Vortioxetine for Post-COVID-19 Condition Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT06091384 - Inspiratory Muscle Strength Training in Post-Covid Syndrome N/A
Not yet recruiting NCT06267300 - Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial Phase 3
Recruiting NCT05986422 - Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Phase 2
Not yet recruiting NCT05534997 - Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome N/A
Recruiting NCT05638633 - Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome Phase 3
Active, not recruiting NCT05630040 - VNS for Long-COVID-19 N/A
Recruiting NCT05841498 - Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome N/A
Enrolling by invitation NCT05981872 - EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19 N/A
Active, not recruiting NCT05543408 - Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial" N/A
Recruiting NCT05817032 - Effect of Telerehabilitation Practice in Long COVID-19 Patients N/A
Recruiting NCT05823896 - imPROving Quality of LIFe In the Long COVID Patient Phase 2
Completed NCT05764070 - Impact of Vagus Nerve Stimulation on Post-Aerobic Activity Recovery in Post SARS-CoV-2 Patients N/A
Completed NCT05765591 - Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome N/A
Recruiting NCT05918965 - Vagus Stimulation in Female Long COVID Patients. N/A
Not yet recruiting NCT06231238 - Balance Acceptance and Commitment Therapy for Long COVID Phase 2
Completed NCT06282627 - The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients
Active, not recruiting NCT05753202 - tDCS in Post-COVID Syndrome: Comparison of Two Targets N/A